As a valued subscriber to the wealth of resources published by Relias Media, we are sending this reminder that your new issue is now available online. The articles in this issue are listed below:
A record resurgence of measles in 2019 includes two large, ongoing outbreaks in New York, where the Centers for Disease Control and Prevention is helping hospitals and outpatient clinics prevent transmission from incoming cases. Read More
Lowering the age of measles immunization for travelers due to international outbreaks, the Centers for Disease Control and Prevention “strongly recommends” that infants six months through 11 months receive one dose of measles, mumps, and rubella vaccine before travel. Read More
An emerging strain of Pseudomonas aeruginosa with a novel mechanism of resistance to most antibiotics has been detected in healthcare outbreaks in Lubbock, TX, and Tijuana, Mexico, the Centers for Disease Control and Prevention reports.
Capable of causing invasive infections, Streptococcus pyogenes (Group A strep) has been susceptible to beta-lactam antibiotics for more than a half century. Ominously, researchers investigating an upsurge of Group A strep cases in Seattle found a mutated strain that confers resistance to ampicillin and other beta-lactam drugs.
Infection preventionists should be vigilant in detecting and preventing drug diversion by healthcare workers, as outbreaks linked to this crime appear to be increasing, says Kimberly New, JD, BSN, RN, founder of Diversion Specialists.
Acute flaccid myelitis — a paralytic condition in children that appeared mysteriously in 2014 — is almost certainly of viral origin and most likely an enterovirus, an investigator with the Centers for Disease Control and Prevention recently reported.
Financial Disclosure: Peer Reviewer Patrick Joseph, MD, reports that he is a consultant for Genomic Health, Siemens, and CareDx. Senior Writer Gary Evans, Editor Jesse Saffron, Editor Jill Drachenberg, Nurse Planner Patti Grant, RN, BSN, MS, CIC, and Editorial Group Manager Leslie Coplin report no consultant, stockholder, speaker’s bureau, research, or other financial relationships with companies having ties to this field of study.
